Navigation Links
Despite the Recent Availability of Xtandi, Zytiga Continues to Dominate the Second-Line Metastatic Castrate-Resistant Prostate Cancer Setting, According to Surveyed U.S. Oncologists and Urologists
Date:3/25/2013

EXTON, Pa., March 25, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceuticals issues, finds that, despite the 2012 launch of Medivation/Astellas Pharma's Xtandi (enzalutamide) for the treatment of docetaxel-pretreated metastatic castrate-resistant prostate cancer (mCRPC), surveyed oncologists report that Johnson & Johnson/Janssen Biotech/Janssen-Cilag's Zytiga continues to dominate the second-line mCRPC setting—although its share dropped marginally from Q3 2012 to Q1 2013. The patient share of Sanofi's Jevtana showed a marked decline over this time period as a result of Xtandi's availability, especially in the third line where Jevtana's patient share in Q1 2013 is half that of its reported share in Q3 2012. The findings are from the TreatmentTrends® Prostate Cancer (US) Q1 2013 report, in which 53 urologists and 51 medical oncologists were surveyed about their current and expected treatment practices for prostate cancer.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36805LOGO )

"In the first-line symptomatic mCRPC setting, docetaxel still dominates treatment according to surveyed oncologists, despite the recent label extension of Zytiga for chemotherapy-naive mCRPC in December 2012," said Decision Resources Group Analyst Khurram Nawaz , M.Sc. "Nevertheless, surveyed oncologists indicate that Zytiga's patient share for first-line symptomatic mCRPC has almost doubled from Q3 2012 to Q1 2013. Interestingly, both surveyed urologists and oncologists indicate that Xtandi is also prescribed for first-line mCRPC patients, although this off-label use remains minimal due to perceived reimbursement challenges."

Surveyed physicians are most satisfied with Zytiga as a treatment for mCRPC; Dendreon's Provenge and mitoxantrone have the lowest levels of overall satisfaction. Satisfaction scores for the efficacy of therapies used to treat mCRPC are similar in Q1 2013 compared with prior waves of research; however, satisfaction with Xtandi in Q1 2013 is greater than the level of satisfaction with Zytiga in Q1 2012.

With respect to emerging therapies, improved efficacy is the most desirable attribute for emerging therapies in mCRPC, but sustained effects and long-term safety are also critical. On average, surveyed urologists more than oncologists prefer oral formulations and therapies that do not require monitoring. Surveyed physicians are more familiar with Algeta/Bayer HealthCare's radium-223 and Bristol-Myers Squibb's Yervoy than they are with other therapies in development for mCRPC. Surveyed physicians rate radium-223—which has been filed with the FDA and EMA, and granted priority review by the FDA—as the therapy in which they are most interested.

TreatmentTrends® Prostate Cancer is a syndicated report designed to provide a view of the current and future management of prostate cancer based on primary research fielded with 50 urologists and 50 medical oncologists in the United States. The report evaluates treatment and diagnosis patterns of the disease and physician opinions on possible future therapy options. BioTrends Oncology is also covering the launch of Xtandi and potential launch of radium-223 through its LaunchTrends® studies.

About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please contact us at www.bio-trends.com.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort
781-993-2597 
ccomfort@dresources.com


'/>"/>
SOURCE BioTrends Research Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Global Spinal Nonfusion Market to Grow to $1 Billion by 2017, Despite Challenges
2. Opportunities Exist Despite Challenges in Chinas API Market
3. Accelerating Drugs to Market - Despite Challenges, Adaptive Clinical Trials Reduce Drug Development Costs and Time to Market
4. According to New Survey, Most Men are Not Proactive about Their Health Despite the Desire to Live Long Lives
5. SafeCode Drug Technologies Initiating Activities to Commercialize its Recent Newly Acquired Technology of the Pain-Free Injection
6. Precision Optics Corporation, Inc. Operating Results for Six Months Ended December 31, 2012 and Recent Operating Activities
7. Vancouver General Hospital Deploys TRU-D Superbug Slayer to Battle Worst Season of Flu in Recent Memory
8. KemPharm Supports Recent FDA Recommendations for Hydrocodone-Containing Compounds and Abuse-Deterrent Opioids
9. Hologic to Showcase 3D Mammography and Other Recent Innovations in Healthcare at the 38th Arab Health Congress in Dubai
10. Starkey Hearing Foundation Founders Bill and Tani Austin Honored by Dalai Lama After Recent Hearing Mission to India
11. Regulus Reports Third Quarter 2012 Financial Results and Recent Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... DUBLIN , May 26, 2017  Endo International plc ... Campanelli , President and CEO, will represent the Company in ... Global Healthcare Conference on Tuesday, June 13, 2017 at 10:40 ... held at Terranea Resort in Rancho Palos Verdes, ... archive for the event will be available on the Company,s ...
(Date:5/23/2017)... 2017  Leaf Healthcare, recognized for developing one ... pressure ulcer prevention, will unveil its comprehensive mobility ... Care Nurses, National Teaching Institute and Critical Care ... Leaf Patient Monitoring System is the first mobility ... The system seamlessly tracks patient movement throughout the ...
(Date:5/18/2017)... May 18, 2017  Two Bayer U.S. Pharmaceutical leaders ... during its recent 28 th Woman of ... event showcases HBA,s longstanding mission of furthering the advancement ... Cindy Powell-Steffen , senior director of ... division, and Libby Howe , a regional business ...
Breaking Medicine Technology:
(Date:5/26/2017)... ... May 26, 2017 , ... Amir Qureshi, MD is the first physician in ... cord stimulation system. The Nuvectra™ Algovita SCS System has been FDA approved as a ... first in Arkansas to introduce the most powerful SCS system and the only stretchable ...
(Date:5/26/2017)... Fla. (PRWEB) , ... May 26, 2017 , ... ... of premium delicatessen foods, is sharing bold recipes for Memorial Day entertaining that ... your menus. , “Boar’s Head fresh sliced meats and cheeses featured in ...
(Date:5/26/2017)... ... 26, 2017 , ... After raising nearly $30,000 on Kickstarter , about ... available at a discounted crowdfunding price on Indiegogo . , “Along with creating ... wanted to bring a fidget toy to the market that was made of superior ...
(Date:5/26/2017)... ... May 26, 2017 , ... Rob Lowe acts as host and ... the series is on hiking in American. Viewers can reconnect with America as it ... of hiking. , Many consumers have looked for an inventive new place for a ...
(Date:5/26/2017)... ... ... Cross”: the personal journey of Bob Massey and his faith in the Lord. “THE ... Massey. Bob Massey is small in stature but big in character. As Johnny ... others is apparent in all of his life decisions. , “I’m in the eightieth ...
Breaking Medicine News(10 mins):